Usual treatments of metastatic renal cell carcinoma are not efficient. Phase II trials using Interferon alpha showed a low response rate (10 to 15%). We have conducted a phase I-II trial using a combination of Vinblastine and Recombinant alpha 2 A Interferon in 21 patients. The response rate is of 43% including 1 complete and 8 partial remissions, 5 stabilizations and 8 progressive diseases. In spite of important side effects, these results are promising.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Results of the Latin American Pediatric Oncology Group (GALOP-2011) Trial for Patients With Localized Ewing Sarcoma: A Multicentric Study of Interval-Compressed Multiagent Chemotherapy.
Pediatr Blood Cancer
January 2025
Department of Clinical Research, Instituto do Câncer Infantil, Porto Alegre, Brazil.
Background: GALOP investigators developed a prospective cooperative protocol for localized Ewing sarcoma (ES) incorporating interval-compressed chemotherapy (VDC/IE, vincristine, doxorubicin, cyclophosphamide/ifosfamide and etoposide). After completing conventional treatment, patients were randomized to 1 year of metronomic chemotherapy (vinblastine and cyclophosphamide).
Methods: Phase III randomized prospective trial.
A novel machine learning-based immune prognostic signature for improving clinical outcomes and guiding therapy in colorectal cancer: an integrated bioinformatics and experimental study.
BMC Cancer
January 2025
School of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou, 215011, China.
Immune cells are pivotal components in the tumor microenvironment (TME), which can interact with tumor cells and significantly influence cancer progression and therapeutic outcomes. Therefore, classifying cancer patients based on the status of immune cells within the TME is increasingly recognized as an effective approach to identify prognostic biomarkers, paving the way for more effective and personalized cancer treatments. Considering the high incidence and mortality of colorectal cancer (CRC), in this study, an integrated machine learning survival framework incorporating 93 different algorithmic combinations was utilized to determine the optimal strategy for developing an immune-related prognostic signature (IRPS) based on the average C-index across the four CRC cohorts.
View Article and Find Full Text PDFReal-world data on utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer: impact on surgical complications and oncological efficacy.
Acta Oncol
January 2025
Institute of Clinical Medicine, UIT- The Arctic University, Tromsø, Norway; Department of Urology, University Hospital of North Norway, Tromsø, Norway.
Background And Purpose: Recommended treatment of urothelial muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy, but there are challenges with low utilization of NAC. We aimed to evaluate the utilization of NAC, perioperative complications and oncological efficacy in a real-world setting.
Patients And Methods: All patients operated with radical cystectomy at the University Hospital of North Norway during 2011-2021 for MIBC were included.
Successful Treatment of a Patient Presenting with Simultaneous Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma: A Case Report.
Am J Case Rep
January 2025
Department of Hematology/Oncology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.
BACKGROUND Simultaneously occuring diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL) is extremely rare. Generally, patients with CD20-positive DLBCL receive rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone (R-CHOP) regimen, while those with HL receive brentuximab vedotin, doxorubicin, vinblastine, dacarbazine (A-AVD) regimen as first-line therapy. Establishing a strategy for treating both lymphoma subtypes concurrently is thus very difficult.
View Article and Find Full Text PDFEnhancement of vindoline and catharanthine production in Catharanthus roseus by LED light and plasma activated water.
PLoS One
December 2024
Department of Agricultural and Food Sciences (DISTAL), University of Bologna, Bologna, Italy.
This study aimed to increase the concentrations of vindoline (VDL) and catharanthine (CAT) in Catharanthus roseus plants cultivated in an indoor farming system using artificial lighting and plasma-activated water (PAW). After a 61-days pre-treatment period under fluorescent lamps, plants were exposed to four treatments: white light (W) from the same fluorescent lamps, red light (R) from LEDs, W with PAW, and R with PAW. These combinations were evaluated at two sampling times: 45 days (T1) and 70 days (T2) after the end of pre-treatment (DAP).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!